Background {#Sec1}
==========

Coronary artery disease (CAD) is the leading cause of death and disability worldwide \[[@CR1], [@CR2]\]. To date, the exact pathogenesis of CAD remains largely unknown. Nevertheless, plenty of evidences demonstrated that genetic factors are crucial for the development of CAD. First, family clustering of CAD was observed extensively, and past twin studies showed that the heredity grade of CAD was over 50 % \[[@CR3], [@CR4]\]. Second, numerous genetic variants were found to be associated with an increased susceptibility to CAD by previous genetic association studies, and screening of common causal variants was also proved to be an efficient way to predict the individual risk of developing CAD \[[@CR5], [@CR6]\]. Overall, these findings jointly indicated that genetic predisposition to CAD is important for its occurrence and development.

Adiponectin (ADIPOQ), an adipocytokine that regulates energy and material metabolism, is implicated in the development of multiple metabolic disorders including obesity and type II diabetes. And it was evident that these two common metabolic disorders were associated with an increased risk of CAD \[[@CR7]\]. Furthermore, previous studies demonstrated that adipoenctin have both anti-atherogenic and anti-inflammatory property \[[@CR8], [@CR9]\]. Moreover, the expression level of adiponectin was also significantly decreased in CAD patients \[[@CR10], [@CR11]\]. Overall, these evidences jointly suggested that adipoenctin might exert favorable protection effects against CAD. Therefore, functional *ADIPOQ* genetic polymorphisms, which may alter the expression level of adiponectin, may also affect individual susceptibility to CAD. Recently, some pilot studies already investigated associations of two common functional *ADIPOQ* polymorphisms, rs1501299 and rs2241766, with the susceptibility to CAD. However, the results of these studies were not consistent, especially when they were conducted in different populations \[[@CR12]--[@CR19]\]. Previous studies failed to reach a consensus regarding associations between *ADIPOQ* polymorphisms and CAD partially because of their relatively small sample sizes. Thus, we performed the present meta-analysis to explore the relationship between *ADIPOQ* polymorphisms and CAD in a larger pooled sample size. Additionally, we also aimed to elucidate the potential effects of ethnic background on associations between *ADIPOQ* polymorphisms and CAD.

Methods {#Sec2}
=======

The current meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist \[[@CR20]--[@CR22]\].

Literature search and inclusion criteria {#Sec3}
----------------------------------------

The combination of following terms: (adiponectin OR ADIPOQ) AND (polymorphism OR variant OR mutation OR genotype OR allele) AND (coronary heart disease OR coronary artery disease OR angina pectoris OR acute coronary syndrome OR myocardial infarction) was used to searched for potentially eligible articles that were published prior to December 1, 2018 in PubMed, Web of Science, Embase and China National Knowledge Infrastructure (CNKI). We also reviewed the reference lists of all retrieved articles for other potentially eligible studies.

To test the research hypothesis of this meta-analysis, included studies must meet all the following criteria: (1) case-control study on associations between *ADIPOQ* polymorphisms (rs1501299 and rs2241766) and CAD; (2) provide genotypic and/or allelic frequency of investigated polymorphisms; (3) full text in English or Chinese available. Studies were excluded if one of the following criteria was fulfilled: (1) not relevant to *ADIPOQ* polymorphisms and CAD; (2) case reports or case series; (3) abstracts, reviews, comments, letters and conference presentations. In the case of duplicate reports by the same authors, we only included the most recent study.

Data extraction and quality assessment {#Sec4}
--------------------------------------

We extracted the following information from eligible studies: 1. name of the first author; 2. year of publication; 3. country and ethnicity of participants; 4. sample size; and 5. genotypic distributions of *ADIPOQ* polymorphisms in cases and controls. The probability value (*p* value) of Hardy-Weinberg equilibrium (HWE) was also calculated.

We used the Newcastle-Ottawa scale (NOS) to evaluate the quality of eligible studies \[[@CR23]\]. The NOS has a score range of zero to nine, and studies with a score of more than seven were thought to be of high quality.

Two reviewers conducted data extraction and quality assessment independently (Xia Zhang and YanJun Cao). When necessary, we wrote to the corresponding authors for extra information. Any disagreement between two reviewers was solved by discussion until a consensus was reached.

Statistical analyses {#Sec5}
--------------------

In the current study, Review Manager Version 5.3.3 was used to perform statistical analyses. We calculated ORs and 95% CIs to estimate potential associations between *ADIPOQ* polymorphisms and CAD in all possible genetic models, and a *p* value of 0.05 or less was defined as statistically significant. Between-study heterogeneities were evaluated by I^2^ statistic. Random-effect models (REMs) would be used for analyses if I^2^ was greater than 50%. Otherwise, analyses would be performed with fixed-effect models (FEMs). Subgroup analyses by ethnicity and type of disease were subsequently carried out. Stabilities of synthetic results were tested in sensitivity analyses. Publication biases were assessed by funnel plots.

Results {#Sec6}
=======

Characteristics of included studies {#Sec7}
-----------------------------------

We found 442 potential relevant articles. Among these articles, totally 45 eligible studies were finally included for pooled analyses (see Fig. [1](#Fig1){ref-type="fig"}). Baseline characteristics of included studies were shown in Table [1](#Tab1){ref-type="table"}.Fig. 1Flowchart of study selection for the present studyTable 1The characteristics of included studiesFirst author, yearCountryEthnicityType of diseaseSample sizeGenotype distribution*P*-value for HWENOS scoreCases Controlsrs1501299 G/TGG/GT/TTAl-Daghri 2011Saudi ArabiaSouth AsianCAD123/29747/57/19111/142/440.8977Ambroziak 2018PolandCaucasianMI188/15388/72/2884/59/100.9337Antonopoulos 2013GreeceCaucasianCAD462/132220/212/3066/50/160.1848Bacci 2004ItalyCaucasianCAD142/23470/65/7118/88/280.0737Boumaiza 2011TunisiaCaucasianCAD213/108105/84/2345/41/180.1158Chen 2011ChinaEast AsianCAD93/10254/33/661/38/30.3077Cheung 2014Hong KongEast AsianCAD182/201088/75/191103/759/1480.2707Chiodini 2010ItalyCaucasianMI1002/503530/392/80239/198/660.0167De Caterina 2011ItalyCaucasianMI1833/1821926/746/161906/767/1480.4197Esteghamati 2012IranSouth AsianCAD114/12776/30/863/47/170.0957Filippi 2005ItalyCaucasianCAD580/466287/241/52266/167/330.3388Gable 2007UKCaucasianMI504/557266/216/22289/225/430.9318Ghazouani 2018TunisiaCaucasianCAD277/269143/93/41138/88/43\< 0.0018Gui 2012ChinaEast AsianCAD410/431172/185/53239/154/380.0728Hegener 2006USAMixedMI341/341183/134/24181/143/170.0938Jung 2006KoreaEast AsianCAD88/6838/43/731/32/50.3997Katakami 2012JapanEast AsianMI213/2424129/71/131229/976/2190.2097Lacquemant 2004UKCaucasianCAD161/30982/66/13169/115/250.3877Li 2018ChinaEast AsianCAD201/14167/107/2764/53/240.0308Liang 2011ChinaEast AsianMI78/8430/43/548/30/60.6637Liang 2017ChinaEast AsianCAD960/962490/388/82617/300/450.2758Mohammadzadeh 2016IranSouth AsianCAD100/10038/55/756/42/20.0637Ohashi 2004JapanEast AsianCAD383/368185/164/34190/149/290.9778Oliveira 2012BrazilMixedCAD450/153209/197/4462/68/230.5427Pischon 2007USAMixedCAD491/988266/182/43485/416/870.8697Qi 2005USAMixedCAD228/594105/111/12293/249/520.9307Rizk 2012QatarSouth AsianACS142/12158/64/2046/59/160.6677Rodr'ıguez-Rodr'ıguez 2011SpainCaucasianCAD119/55569/44/6287/224/440.9757Wu 2013ChinaEast AsianCAD188/20067/108/1392/90/180.5457Zhang 2015ChinaEast AsianCAD561/412309/209/43214/170/280.4598Zhang 2018ChinaEast AsianCAD717/612583/126/8471/131/100.7988rs2241766 T/GTT/TG/GGAl-Daghri 2011Saudi ArabiaSouth AsianCAD122/29877/35/10220/72/60.9697Antonopoulos 2013GreeceCaucasianCAD462/132359/97/699/29/40.3098Bacci 2004ItalyCaucasianCAD130/22090/35/5149/60/110.1357Boumaiza 2011TunisiaCaucasianCAD212/104145/57/1075/24/50.1118Chang 2009TaiwanEast AsianCAD600/687316/238/46309/399/790.6067Chen 2011ChinaEast AsianCAD93/10268/19/659/35/80.3917Cheung 2014Hong KongEast AsianCAD184/201289/83/121007/822/1830.4137Chiodini 2010ItalyCaucasianMI1002/503679/304/19359/126/180.1027Di 2011ChinaEast AsianCAD196/12491/85/2065/50/90.8847Du 2016ChinaEast AsianCAD493/304253/190/50185/97/220.0698Esteghamati 2012IranSouth AsianCAD114/12748/41/2568/46/130.2227Foucan 2010French West IndiesAfricanCAD57/159NANANA7Gable 2007UKCaucasianMI526/563360/154/12384/168/110.2808Ghazouani 2018TunisiaCaucasianCAD277/269181/74/22182/70/170.0078Hegener 2006USAMixedMI341/341241/95/5252/80/90.3898Jin 2009ChinaEast AsianCAD110/7353/48/950/20/30.5848Jung 2006KoreaEast AsianCAD88/6841/40/734/30/40.4317Lacquemant 2004UKCaucasianCAD162/315109/48/5249/57/90.0157Li 2011ChinaEast AsianCAD118/9751/46/2154/31/120.0368Liang 2017ChinaEast AsianCAD960/982471/382/107608/308/460.3878Luo 2010ChinaEast AsianCAD221/100100/99/2250/41/90.8867Mofarrah 2016IranSouth AsianCAD152/7282/35/3556/13/30.0728Mohammadzadeh 2016IranSouth AsianCAD100/10075/24/165/31/40.9007Nan 2012ChinaEast AsianCAD213/467115/84/14237/191/390.9538Oliveira 2012BrazilMixedCAD450/153323/114/13117/33/30.7087Pischon 2007USAMixedCAD482/979374/102/6759/202/180.2907Qi 2005USAMixedCAD219/599NANANA7Rizk 2012QatarSouth AsianACS142/12262/42/3856/49/170.2457Sabouri 2011IranSouth AsianCAD329/241253/74/2205/35/10.7037Xu 2010ChinaEast AsianCAD153/7378/65/1050/20/30.5848Zhang 2011ChinaEast AsianCAD149/16763/60/2697/50/200.0027Zhang 2015ChinaEast AsianCAD561/412276/235/50224/164/240.3998Zhang 2018ChinaEast AsianCAD717/612500/184/33456/149/70.1778Abbreviations: *CAD* Coronary artery disease, *MI* Myocardial infarction, *ACS* Acute coronary syndrome, *HWE* Hardy-Weinberg equilibrium, *NOS* Newcastle-Ottawa scale, *NA* Not available

Overall and subgroup analyses {#Sec8}
-----------------------------

Results of overall and subgroup analyses were summarized in Table [2](#Tab2){ref-type="table"}. To be brief, a significant association with the susceptibility to CAD was detected for rs2241766 (dominant model: *p* = 0.0009, OR = 0.82, 95%CI 0.73--0.92; recessive model: *p* = 0.04, OR = 1.29, 95%CI 1.02--1.64; allele model: *p* \< 0.0001, OR = 0.80, 95%CI 0.73--0.88) polymorphism in overall analyses. Further subgroup analyses by ethnicity revealed that rs1501299 polymorphism was significantly associated with the susceptibility to CAD in East Asians, whereas rs2241766 polymorphism was significantly associated with the susceptibility to CAD in Caucasians, East Asians and South Asians. No any other positive results were observed in overall and subgroup analyses (see Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}).Table 2Results of overall and subgroup analyses for *ADIPOQ* polymorphisms and CADPopulationSample sizeDominant comparisonRecessive comparisonOverdominant comparisonAllele comparison*P* value OR (95%CI) I^2^ statistic*P* value OR (95%CI) I^2^ statistic*P* value OR (95%CI) I^2^ statistic*P* value OR (95%CI) I^2^ statisticrs1501299 G/TGG vs. GT + TTTT vs. GG + GTGT vs. GG + TTG vs. TOverall11,544/156420.30 0.94 (0.84--1.05) 73%0.42 0.94 (0.80--1.10) 57%0.08 1.09 (0.99--1.19) 60%0.71 0.98 (0.90--1.08) 76%Caucasian5481/51070.82 1.01 (0.93--1.09) 39%0.12 0.80 (0.61--1.06) 67%0.29 1.04 (0.96--1.13) 2%0.47 1.04 (0.93--1.17) 64%East Asian4074/78140.08 0.82 (0.66--1.03) 82%**0.03 1.20 (1.02--1.42)** 40%0.10 1.18 (0.97--1.43) 76%0.14 0.88 (0.74--1.04) 80%South Asian479/6450.88 1.04 (0.61--1.77) 78%0.97 0.99 (0.68--1.45) 42%0.79 0.95 (0.65--1.38) 55%0.90 1.03 (0.68--1.56) 80%MI4159/58830.67 1.04 (0.87--1.23) 65%0.63 0.91 (0.63--1.32) 74%0.42 0.96 (0.88--1.05) 47%0.71 1.03 (0.88--1.21) 75%rs2241766 T/GTT vs. TG + GGGG vs. TT + TGTG vs. TT + GGT vs. GOverall10,135/11577**0.0009 0.82 (0.73--0.92)** 67%**0.04 1.29 (1.02--1.64)** 63%0.08 1.12 (0.99--1.27) 71%**\< 0.0001 0.80 (0.73--0.88)** 67%Caucasian2771/21060.09 0.89 (0.79--1.02) 27%0.39 0.87 (0.62--1.20) 0%**0.04 1.15 (1.01--1.32)** 33%0.24 0.93 (0.84--1.05) 20%East Asian4856/6280**0.02 0.80 (0.66--0.96)** 77%0.06 1.35 (0.99--1.84) 68%0.30 1.12 (0.90--1.40) 83%**0.0006 0.80 (0.71--0.91)** 66%South Asian959/960**0.04 0.69 (0.48--0.99)** 66%**\< 0.0001 2.67 (1.82--3.91)** 39%0.76 1.05 (0.76--1.46) 56%**0.01 0.64 (0.45--0.91)** 76%MI1869/14070.19 0.90 (0.77--1.05) 0%0.11 0.68 (0.43--1.09) 18%0.06 1.16 (0.99--1.36) 30%0.48 0.95 (0.83--1.09) 0%Abbreviations: *OR* Odds ratio, *CI* Confidence interval, *NA* Not available, *CAD* Coronary artery disease, *MI* Myocardial infarctionThe values in bold represent there is statistically significant differences between cases and controlsFig. 2Forest plots for overall analyses of investigated polymorphisms. **a** Forest plot of rs1501299 polymorphism and CAD under dominant comparison; **b** Forest plot of rs1501299 polymorphism and CAD under recessive comparison; **c** Forest plot of rs1501299 polymorphism and CAD under overdominant comparison; **d** Forest plot of rs1501299 polymorphism and CAD under allele comparison; **e** Forest plot of rs2241766 polymorphism and CAD under dominant comparison; **f** Forest plot of rs2241766 polymorphism and CAD under recessive comparison; **g** Forest plot of rs2241766 polymorphism and CAD under overdominant comparison. **h** Forest plot of rs2241766 polymorphism and CAD under allele comparison

Sensitivity analyses {#Sec9}
--------------------

We performed sensitivity analyses by excluding studies that deviated from HWE. No alterations of results were detected in sensitivity analyses, which suggested that our findings were statistically reliable.

Publication biases {#Sec10}
------------------

Publication biases were evaluated with funnel plots. We did not find obvious asymmetry of funnel plots in any comparisons, which indicated that our findings were unlikely to be impacted by severe publication biases.

Discussion {#Sec11}
==========

Based on combined analyses of 45 eligible studies, our study showed that rs1501299 and rs2241766 polymorphisms were both significantly associated with the susceptibility to CAD in certain populations, which suggested that these two polymorphisms may be used to identify individuals with higher susceptibility to CAD. There are two possible explanations for our positive findings. First, genetic variations of the *ADIPOQ* gene may lead to alternations in gene expression or changes in ADIPOQ protein structure, which may subsequently affect biological functions of ADIPOQ and ultimately impact individual susceptibility to CAD. Second, it is also possible that *ADIPOQ* polymorphisms may be linked to each other or even linked to other unidentified genes, which could also impact individual susceptibility to CAD.

There are several points that should be noted about this meta-analysis. Firstly, previous experimental studies demonstrated that mutant alleles of investigated polymorphisms could lead to decreased adiponectin generation, which may partially explain our positive findings \[[@CR12]--[@CR19]\]. Secondly, it is also worth noting that for rs1501299 polymorphism, the trends of associations in different ethnicities were not always consistent, and this may be attributed to ethnic differences in genotypic distributions of investigated polymorphisms. However, it is also that these inconsistent findings may be resulted from a complex interaction of both genetic and environmental factors. Thirdly, it should be noted that significant between-study heterogeneities were observed in all genetics comparisons of overall analyses, which may partially attributed to ethnic and racial differences of eligible studies. To overcome between-study heterogeneities, REMs were used for pooled analyses, and in further subgroup analyses, we noticed that between-study heterogeneities among studies that were conducted in Caucasians were relatively small, which also supported that ethnic background could impact individual susceptibility to CAD. Fourthly, a recent meta-analyses conducted by Hou et al. \[[@CR24]\] also tried to explore potential associations between *ADIPOQ* polymorphisms and CAD. However, our findings should be considered as more conclusive compared to that of previous meta-analysis since many related studies were published in the last three years, which warranted an update meta-analysis. Totally 10 more eligible studies were enrolled in our pooled analyses, and the sample sizes of our analyses were also significantly larger than that of previous meta-analyses, which could significantly reduce the risk of obtaining false positive or false negative results. Compared with the previous meta-analysis, similar positive results were detected for rs2241766 polymorphism in overall and subgroup analyses. However, positive results in Caucasians for rs1501299 polymorphism were no longer observed in our meta-analysis. Instead, we found that rs1501299 polymorphism could impact individual susceptibility to CAD in East Asians under recessive genetic model. Therefore, future studies with larger sample sizes are still needed to test the potential associations between *ADIPOQ* polymorphisms and CAD, especially for rs1501299 polymorphism. Fifthly, our study only focused on two mostly investigated *ADIPOQ* polymorphisms, and future meta-analyses should try to investigate the associations between CAD and other common *ADIPOQ* polymorphisms such as rs266729, rs822395 and rs17300539. These polymorphisms were not analyzed by us because we failed to find any additional eligible studies compared to the previous meta-analysis conducted by Hou et al. \[[@CR24]\].

Some limitations of this meta-analysis should also be acknowledged when interpreting our findings. First, our pooled analyses were based on unadjusted estimations due to lack of raw data, and failure to perform further adjusted analyses may impact the reliability of our findings \[[@CR25], [@CR26]\]. Second, since our pooled analyses were based on retrospective case-control studies, despite our positive findings, future perspective studies are still needed to examine whether there is direct causal relationship between *ADIPOQ* polymorphisms and CAD \[[@CR27], [@CR28]\]. Third, associations between *ADIPOQ* polymorphisms and CAD may also be modified by gene-gene and gene-environmental interactions. However, due to lack of raw data, we could not conduct relevant analyses \[[@CR29], [@CR30]\]. Fourth, our analyses were based on retrospective case-control studies. Thus, despite the relatively high NOS score, it was still possible that our findings might be impacted by potential selection, measurement and confounding biases. Taking the above mentioned limitations into consideration, our findings should be interpreted with caution.

Conclusions {#Sec12}
===========

In conclusion, our meta-analysis suggested that rs1501299 and rs2241766 polymorphisms were both significantly associated with the susceptibility to CAD in certain populations. However, further well-designed studies are still warranted to confirm our findings.
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